**Imeglimin** (IME), a new oral anti-diabetic drug for managing Type 2 Diabetes has emerged as an effective alternative to **metformin** (MET).

According to a recent randomized controlled clinical trial, IME was found to enhance both **glucose-dependant insulinotropic peptide (GIP)** and **glucagon-like peptide-1 (GLP-1)** secretion, in addition to its direct insulin-boosting effects.

- Over **24 weeks**, patients treated with IME showed comparable HbA1c and blood glucose levels reductions to those on MET, but insulin levels were increased only in IME.
- Interestingly, while an increase in insulin levels in IME was positively correlated with an increase in GLP-1 at **12 weeks**, it was associated only with an increase in GIP at **24 weeks**.

*These findings underscore Imeglimin’s potential as a promising therapeutic option for improved glucose control in diabetes care.*   
                                                                                                                                                                        Source: Diabetes, Obesity and Metabolism [Read full story](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16086?af=R)